- Trial phase
- Not stated
- Time to market
- Not stated
- Why 1/10
- No hard, dated catalyst exists for "ARGX-124" because the drug could not be identified in any available source. With no identifiable drug, no catalyst can be scored.
"ARGX-124" could not be identified as an existing drug candidate in any public or internal database. Investors should verify the correct drug name or code before making any trading decisions. Argenx's known near-term catalysts are the myositis Phase 3 readout (expected Q3 2026) and the MMN Phase 3 readout (expected Q4 2026) for its approved/commercial-stage assets.
Price Chart
Executive Summary
No evidence of a drug called "ARGX-124" was found in any available source. Argenx SE (Nasdaq: ARGX) is a commercial-stage immunology company whose known pipeline includes efgartigimod (VYVGART, approved), ARGX-117 (Phase 2, multifocal motor neuropathy), ARGX-119 (Phase 2, ALS, terminated), empasiprubart (Phase 2/3), and FB102 (anti-CD122, preclinical/Phase 1 via Forte acquisition). The code "ARGX-124" does not appear in clinical trial registries, FDA records, press releases, SEC filings, or any internal database. It may be a very early preclinical candidate not yet publicly disclosed, a discontinued program, or a typo.
How It Works
Unknown, drug candidate could not be identified.
Trial Status
No clinical trial records found for "ARGX-124" in any available database.
The Two-Sided Case
Upcoming Catalysts
- ["No catalysts identified for "ARGX-124" because the drug could not be identified."]
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARGENX SE 6-K ARGX ·Originating report